CAUSES OF DEATH IN PATIENTS WITH STAGE 0-II BREAST CANCER

Authors

  • Manuela URSARU University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi
  • Irina JARI University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi
  • A. NAUM University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi
  • V. SCRIPCARIU University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi
  • D. NEGRU University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi

Abstract

Aim: To analyze the main causes of death in patients with stage 0-II breast cancer who undergo breast conserving surgery or radical mastectomy, and to establish the role of imaging surveillance protocols following breast cancer treatment. Material and methods: We conducted a retrospective medical record review between January 2005 and December 2012, when breast cancer was the primary cause of death for 113 inpatients.  All patients were admitted to the Oncology Clinic of the Iasi Regional Cancer Institute (IRCI), Romania. Patients were stratified by clinical stage 0, I and II, of which 33 (29.2%) patients were managed by breast conservation therapy and 80 (70.8%) underwent radical mastectomy. From the patient medical records all diagnostic imaging studies performed (ultrasound, radiography and computed tomography) were identified and analyzed according to a standard protocol for imaging the postoperative breast. Results: Bone, liver, lung, lymph nodes and local-regional recurrence were the most common sites for metastasis, while the most frequent cause of death were metastases to the liver, pleura, lung and brain. The time interval between recurrence and death ranged from 0-24 years among patients with one type of metastasis, and decreased to 0-3 years since the last recurrence for patients with multiple metastases. Conclusions: The current imaging protocol for monitoring the postoperative breast could be optimized to improve the prognosis and quality of life in patients with stage 0-II breast cancer.

Author Biographies

  • Manuela URSARU, University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Surgery

  • Irina JARI, University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Surgery

  • A. NAUM, University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Morpho-Functional Sciences

  • V. SCRIPCARIU, University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Surgery

  • D. NEGRU, University of Medicine and Pharmacy”Grigore T. Popa” - Iaşi

    Faculty of Medicine
    Department of Surgery

References

1. Chamorey E, Ettore F, Largillier R, Mouret-Reynier MA, et al. Épidémiologie et diversité des cancers du sein N− Étude sur une cohorte de plus de 5 000 patientes traitées au Centre Antoine Lacassagne (Nice, France). In: Namer M, Héry M, Spielmann M, Gligorov J, Penault-Llorca F, eds. Cancer du sein. Paris: Springer, 2012; 441-456.
2. Tarvidon A, Malhaire C. Cancer du sein. Epidemiologie, facteurs de risque, imagerie. Encycl Med Chir 2009; 34-800-A-40: 1-30.
3. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the zear 2012, Ann Oncol 2012; 23(4):1044-1052.
4. Kataja V, Castiglione M. Recomandările Societăţii Europene de Oncologie Medicală (ESMO) pentru diagnosticul, tratamentul şi urmărirea postterapeutică, în afecţiunile oncologice. Ann Oncol 2009; 20(4): 10–14.
5. Georgescu R, Coroş MF, Stolnicu S, et al. Factori prognostici în cancerul mamar (Prognostic factors in breast cancer ). Rev Med Chir Soc Med Nat Iaşi 2012; 116(1): 262-267.
6. Lauratet-Huguenin B, Deniaud-Alexandre É, Genestie C, Bensaid S, et al. Récidives locales après traitement conservateur des cancers du sein: place de la chirurgie. Bull Cancer 2004; 91(11): 821-826.
7. Enkaoua EA. Prise en charge chirurgicale des métastases osseuses vertébrales d’origine mammaire. In: Namer M, Héry M, Spielmann M, Gligorov J, eds. Cancer du sein en situation métastatique. Paris: Springer, 2010; 119-127.
8. Benchimol D. Métastases viscérales du cancer du sein. In: Namer M, Héry M, Spielmann M, Gligorov J , eds. Cancer du sein en situation métastatique. Paris: Springer, 2010; 87-90.
9. Lu WL, Jansen L, Post WJ, et al. Impact on survival of early detection of isolated breast recurrence after the primary treatment for breast cancer: a meta-analasys. Breast Cancer Rest Treat 2009; 114: 403-412.
10. Moisii L, I Jari. Diagnosticul radioimagistic al afecţiunilor aparatului respirator. În: Negru D, ed. Radiologie şi Imagistică Medicală. Iaşi: Ed. Gr. T. Popa UMF Iaşi, 2007; 152-154.
11. Badea R. Ficatul. În: Badea R, ed. Tratat de ultrasonografie clinică. Bucureşti: Ed. Medicală, 2004; 150-153.
12. Gachet J, Giroux J, Girre V, Brain E. Metastases cerebrales dans les cancers du sein. Epidemiologie et histoire naturelle. Experience de l’Institut Curie a travers deux etudes: les patientes Her2- de moins de 65 ans et les patientes de plus de 65 ans. Bull Cancer 2011; 98(4): 357-369.
13. Bachelot T, Le Rhun E, Labidi Gally I. Traitements systemiques des metastases cerebrales des cancers du sein: chimiothérapies cytotoxiques et thérapies ciblees. Bull Cancer 2013; 100(1): 84-90.

Additional Files

Published

2015-06-30

Issue

Section

INTERNAL MEDICINE - PEDIATRICS